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Although angiotensin receptor blockers have different
receptor binding properties no comparative studies with
cardiovascular disease (CVD) end points have been
performed within this class of drugs. The aim of this study
was to test the hypothesis that there are blood pressure
independent CVD-risk differences between losartan and
candesartan treatment in patients with hypertension with-
out known CVD. Seventy-two primary care centres in
Sweden were screened for patients who had been
prescribed losartan or candesartan between the years
1999 and 2007. Among the 24943 eligible patients, 14100
patients were diagnosed with hypertension and prescribed
losartan (n¼6771) or candesartan (n¼7329). Patients
were linked to Swedish national hospitalizations and death
cause register. There was no difference in blood pressure
reduction when comparing the losartan and candesartan
groups during follow-up. Compared with the losartan
group, the candesartan group had a lower adjusted hazard
ratio for total CVD (0.86, 95% confidence interval (CI) 0.77–
0.96, P¼0.0062), heart failure (0.64, 95% CI 0.50–0.82,
P¼0.0004), cardiac arrhythmias (0.80, 95% CI 0.65–0.92,
P¼0.0330), and peripheral artery disease (0.61, 95% CI
0.41–0.91, P¼0.0140). No difference in blood pressure
reduction was observed suggesting that other mechan-
isms related to different pharmacological properties of the
drugs may explain the divergent clinical outcomes.
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Introduction
Hypertension is an important risk factor for the
development of cardiovascular disease (CVD), and
blood pressure lowering treatments have preventive
effects.
1 Several studies comparing antihypertensive
agents have shown differences in risk reduction in
CVD with a similar blood pressure lowering effect,
suggesting that specific pharmacological mechan-
isms may be involved.
2–4 The renin-angiotensin
system (RAS) is targeted by some of the most widely
used antihypertensive medication classes: angioten-
sin converting enzyme inhibitors and angiotensin
receptor blockers (ARBs). ARBs are increasingly
used in the treatment of hypertension because of
fewer side effects than angiotensin converting
enzyme inhibitors, combined with similar blood
pressure lowering abilities.
5,6
The RAS provides the most powerful regulation of
blood pressure and angiotensin II is the primary
mediator in this system. The binding of angiotensin
II to an AT1 receptor produces a number of
potentially harmful effects that include increased
blood pressure, progression of atherosclerosis, myo-
cardial-, and vascular hypertrophy. Losartan was the
first ARB and has been shown to reduce the risk of
stroke and new onset diabetes compared to ateno-
lol.
4 A more recently developed ARB is candesartan,
which has also shown a proven benefit in the
treatment of heart failure and the prevention of
stroke and new onset diabetes.
7–9 Although they
belong to the same class of drugs, losartan and
candesartan have important pharmacological differ-
ences.
10 The binding to the AT1 receptor is tighter
and lasts longer with candesartan compared to
losartan.
10–12
Although losartan and candesartan have, in
several large randomized clinical trials, documented
effect on CVD-risk reduction, no head-to-head
comparison studies have been performed. The
established approach to study differences between
the two drugs is a randomized controlled trial.
13
Such a trial would, however, take 5–10 years and
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In addition, it is difficult to justify from a health
political perspective. The randomized controlled
trials also differ from a real life clinical setting as
there is a selection of both physicians and patients;
the treatment alternatives depend on the study
protocol and the study itself may compromise
patient–doctor relationships.
14 We therefore studied
a real life clinical situation by electronically extract-
ing patient data from electronic primary care
journals and mandatory Swedish national registers
for death and hospitalization.
15,16
The aim of this study was to test the hypothesis
that losartan and candesartan have different effects
on CVD-risk reduction in a real life setting with
primary hypertensive treatment.
Methods
The study protocol was reviewed and approved by
the regional research ethics committee in Uppsala,
Sweden and registered with ClinicalTrials.gov,
number NCT00620178.
Patients eligible for the study were males or
females, more than 17 years of age who were
prescribed candesartan (Anatomical Therapeutic
Chemical (ATC) classification system: C09CA06,
C09DA06) or losartan (ATC: C09CA01, C09DA01)
for hypertension in the period 1 January 1999–31
December 2007. The first prescription found in the
primary care journals within the study period was
defined as the index prescription (treatment onset).
Exclusion criteria were a prior history of CVD and
on-going malignancy (with the exception of basal
cell or squamous cell carcinoma of the skin) found
in primary care journals or the Swedish Hospital
Discharge Register. Patients who were prescribed
vitamin K antagonists, digitalis glycosides, or ni-
trates within 15 months prior to the index prescrip-
tion were also considered to have potential CVD and
were excluded. The remaining exclusion criterion
was the prescription of an RAS inhibitor, other than
the study medications within 1 week after index
prescription.
In Sweden, blood pressure measurements are
performed according to standardized methods,
using the manual Korotkoff method or automatic
measurements. Sweden has extensive use of well-
calibrated blood pressure equipment and measure-
ments are mostly performed by public health nurses.
The patients are told to avoid coffee and tobacco
30min before the examination. After 5min rest in
either the supine or sitting position an appropriate
sized cuff is placed on the over arm. Heart rate is
measured for 1min before blood pressure measure-
ment. Communication with the patient is normally
not recommended. When several readings are
performed, the calculated mean is recorded. A
detailed report of blood pressure readings in the
Swedish primary care concluded that public health
nurses had an overall correct technique.
17 When
analysing the extracted data, the baseline value for
blood pressure was calculated as the mean of the
three last available blood pressures during the time
period 15 month before index prescription until 14
days after index prescription. Blood pressure at 6
months was calculated as the mean of recorded
blood pressures during the time period 2 weeks–6
months after index prescription. From 6 months and
onwards, consecutive blood pressure values were
calculated as the mean of recorded blood pressures
from 0.5 years before and 0.5 years after the specific
time point.
The primary composite end point consisted of
CVD morbidity, CVD mortality, and elective coron-
ary revascularization procedures. CVD was defined
as heart failure (International Classification of
Diseases (ICD): I50, ICD-9: 428), cardiac arrhythmias
(ICD-10: I46–I48, ICD-9: 427), peripheral artery
disease (ICD-10: I70, I71, I74, ICD-9: 440, 441,
444), chronic ischemic heart disease (ICD-10: I20.9,
I25.1, ICD-9: 413–414), myocardial infarction (ICD-
10: I21–I23, ICD-9: 410, 411, 429), stroke (ICD-10:
I61, I63–I64, G45, ICD-9: 431–434, 435), unstable
angina (ICD-10: I20.0, ICD-9: 411), and coronary
revascularization. Cardiovascular mortality was de-
fined as death due to CVD with the above diagnoses.
Diabetes was registered separately (ICD-10: E10–
E14, ICD-9: 250).
In Sweden, a patient has only one general
practitioner who follows the patient. Both nurses
and physicians in a primary care centre have access
to the electronic patient journal and are responsible
for documenting their examinations. The patient
journal is continuously updated with external data
(that are radiologic results, ultrasound examina-
tions, hospital discharge data, and laboratory data).
The selected 72 primary care centres had to use the
same patient journal system to be eligible for
participation.
18 Generally, the use of electronic
patient journals, both in private and public care, is
very common in Sweden. The selected journal
system was the most widely used patient journal
system, having approximately 20000 users, 57% of
all primary care centres in Sweden. No formal
randomization of the primary care centres was
conducted. However, an effort was made in the
recruitment of study sites to ensure a representative
selection of primary care centres. Selection of study
sites was based on the following criteria to ensure a
representative sample of the Swedish population: a
mix of rural and urban areas; public and private care
providers; small, midsized, and large primary care
centres. The use of ARBs was not considered when
selecting study sites, and the centres were included
by a written invitation. The final selection of centres
for the study included 39 public primary care
centres located in 5 of the 21 Swedish county
councils and 33 private care centres located in 7 of
the counties. With regards to size, 13 (18%) small
clinics, 12 (17%) midsize clinics, and 47 (65%) large
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communities inhabiting o15000 people, 36 of the
sites were considered rural and 36 sites were
defined as urban. This sample represents 4.7% of
the total number of public care centres and 14.7% of
the total number of private care centres in Sweden.
Age or other characteristics of the physicians was
not considered in the selection.
Patient data were extracted from primary care
centre servers using a software system, which has
also been used in earlier studies.
19–22 The program
scanned all patient journals at the participating
primary care centres and identified all patients
who were prescribed losartan or candesartan. The
patient’s social security number was replaced with
a study ID when processing the data. Data from 100
patient journals at 25 primary care centres were
manually compared with the study database to
ensure that the software system had extracted
correct patient data. No discrepancies were found.
The date of admission and discharge diagnoses
and causes of death were collected from the
Swedish Hospital Discharge and Cause of Death
Registers.
15,16 The merging of data from primary care
and hospital registers was performed by the Swed-
ish National Board of Health and Welfare.
Statistical methods
The data were processed and analysed at an
independent statistical contract company, and the
study database was managed by the Department of
Public Health and Caring Sciences, Uppsala Uni-
versity, Uppsala, Sweden.
The included patients were only eligible for the
analysis as long as they continued treatment with
the losartan or candesartan. The observation period
ended on the date when the patient died, started a
new RAS inhibiting drug or until the last valid day
of the index prescription.
All descriptive data are given as mean or propor-
tion. The difference in continuous and categorical
data was analysed with t-test and w
2 test, respec-
tively. We used proportional hazards regression to
compute hazard ratio (HR) and 95% confidence
interval (CI). In the primary survival model, adjust-
ments were made for age, gender, diabetes, and
prescription index year. Additional adjustments in
the primary survival model were considered as
sensitivity analyses. Kaplan–Meier curves were used
to illustrate risk development during follow-up. If one
patient had several end points, only the first was used
in the survival model. Although the maximum
observation period was 108 months, the x axis for
the plots was truncated at 96 months because of low
number of observations after this time.
To assess the difference in discontinuation we
removed x number of discontinued subjects from
the losartan group, which gave a similar proportion
of discontinued subjects as that in the candesartan
group (that is 24.8%). When performing the sensi-
tivity analysis, only discontinuation before a CVD
event could be used. The patient numbers therefore
differs slightly from the discontinuation reported for
the total observation time. An HR that remains
similar, compared to the primary survival models,
will support the main results. By solving the
equation (1880 x/6771 x¼1819/7329), x was
found to be 265. All statistical analyses were
performed using R version 2.7.2.
23
Results
Among 24943 eligible patients; 14100 (56.5%)
were included in the study (Figure 1). The number
of discontinued patients was significantly higher in
the losartan group compared to the candesartan
group, 31.4% (n¼2123) vs 27.5% (n¼2015,
Po0.0001). Patients who were initially treated with
losartan were also more frequently converted to
another RAS inhibitor compared with candesartan-
treated patients 13.9% (n¼939) vs 10.8% (n¼788,
Po0.0001) during the study. Other reasons for
discontinuations were death (2.3% (n¼155) vs
2.1% (n¼156, P¼0.1588), in the losartan group
and the candesartan group, respectively) or cessa-
tion of study drug prescription (15.2% (n¼1029] vs
14.6% (n¼1071, P¼0.3768), in the losartan group
and the candesartan group, respectively).
To assess the effects of the difference in disconti-
nuation, 265 discontinued subjects from the losartan
group were omitted to obtain the proportion of
discontinued subjects equal to the candesartan
group, and the survival models were re-run. The
265 discontinued subjects were selected in three
different ways: subjects with shortest exposure time,
subjects with longest exposure time, and randomly
in 1000 repeated analyses. None of these analyses
changed the conclusions as compared with the
primary survival model (data on file).
The proportion of included patients per year, from
1999 to 2007, was similar when comparing the
losartan and candesartan group (data on file). All 72
primary care centres prescribed both losartan
and candesartan, although in various ratios. The
6771 (52.1%) losartan patients
10843 patients were excluded:
￿ 5792 (44.6%) losartan and 4144 (34.7%) candesartan patients with a
  history of cardiovascular disease and/or prescription of
  warfarin/digitalis/nitrates before index prescription
￿ 386 (3.2%) losartan and 379 (2.9%) candesartan patients with
 malignancy
￿ Prescribed another RAAS* inhibitor in the first week after index
  prescription, losartan 59 (0.5%) and candesartan 83 (0.7%) 
7329 (61.4%) candesartan patients
24943 patients started prescription of losartan (13001)
or candesartan (11942) from 1999 to 2007
Figure 1 Patient flow.
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linear range from 7 to 85% among the centres.
The losartan group were older (þ0.7 years),
had lower systolic and diastolic blood pressu-
res ( 1/ 1mmHg), had higher blood glucose
(þ0.1mmoll
 1), had higher HbA1c (þ0.1%), and
had a higher prevalence of diabetes (þ2.8%), were
less frequently treated with thiazides ( 2.3%) and
b-blockers ( 2.0%) and more frequently treated with
glucose lowering drugs (þ1.7%), statins (þ1.3%),
and antithrombotics (þ0.8%) compared with the
candesartan group (Table 1).
Some blood pressure recordings were absent at all
time points. Figure 2 shows the similar blood
pressure levels that were recorded during the
follow-up, and also the number of missing values.
The frequency of blood pressure recordings was
equal in both groups. When calculating 95% CIs for
the blood pressures values at each time point, no
significant differences between the losartan and
candesartan group were observed (data on file).
During the study (median follow-up 2.0 years,
maximal follow-up 9.0 years, and 36339 patient
years), 676 CVD events occurred in the losartan
group, and 575 in the candesartan group (Table 2).
The cumulative incidence of the primary composite
end point was lower in the candesartan group
compared to the losartan group (Figure 3) and the
adjusted HR was 0.86 (95% CI 0.77–0.96, P¼0.0062)
(Table 2).
Figure 4 illustrates the risk development among
six separate end points. The cumulative incidence
of heart failure, cardiac arrhythmias, and peripheral
artery disease was lower with candesartan than
losartan (Figure 4, panels a, b, and c). Compared to
losartan, the adjusted HR was lower for heart failure
0.64 (95% CI 0.50–0.82, P¼0.0004), cardiac ar-
rhythmias 0.80 (95% CI 0.65–0.98, P¼0.0330), and
peripheral artery disease 0.61 (95% CI 0.41–0.91,
P¼0.0140) in the candesartan group (Table 2).
Cardiac arrhythmias were mainly because of atrial
fibrillation (n¼193, 91.9%), which had a separate
adjusted HR of 0.77 (95% CI 0.62–0.95, P¼0.0170).
Chronic ischemic heart disease, myocardial in-
farction, and stroke showed similar cumulative
incidence in both groups (Figure 4, panels d, e,
and f, respectively). The losartan group showed a
small non-significant, increased incidence of the
following events: chronic ischemic heart disease,
myocardial infarction, stroke, hospitalization for
unstable angina, elective coronary revascularization,
cardiovascular mortality, total mortality, and new
onset diabetes compared with the candesartan group
(Table 2). No differences in risk for these events
were found in proportional hazards regression
models. Chronic ischemic heart disease was the
exception and had an unadjusted lower risk in
the candesartan group (0.80 (95% CI 0.66–0.99,
P¼0.0350)) compared with the losartan group.
Table 1 Baseline data from 14100 hypertensive patients without
previous cardiovascular disease
Losartan
(n¼6771)
Candesartan
(n¼7329)
P value
Age (years) 62.4 (12) 61.7 (12) 0.0010
Women, n (%) 3723 (55.0) 4109 (56.1) 0.2030
Body mass index (kg/m
2) 30.2 (5.3) 30.2 (5.4) 0.8463
Systolic blood pressure
(mmHg)
159 (20) 160 (19) 0.0124
Diastolic blood pressure
(mmHg)
89 (10) 90 (10) o0.0001
Total cholesterol (mmoll
 1) 5.7 (1.0) 5.7 (1.1) 0.2243
LDL cholesterol (mmoll
 1) 3.34 (0.81) 3.39 (0.81) 0.0647
HDL cholesterol (mmoll
 1) 1.38 (0.32) 1.37 (0.31) 0.4826
Triglycerides (mmoll
 1) 1.64 (0.81) 1.62 (0.78) 0.2965
Glucose (mmoll
 1) 6.3 (2.4) 6.2 (2.3) 0.0024
HbA1c (%) 5.9 (1.4) 5.8 (1.4) 0.0342
Diabetes, n (%) 1215 (17.9) 1112 (15.2) o0.0001
Serum creatinine (mmoll
 1) 84 (21) 84 (19) 0.6895
Potassium (mmoll
 1) 4.0 (0.4) 4.0 (0.4) 0.7452
Thiazides, n (%) 848 (12.5) 1087 (14.8) 0.0001
Calcium channel blockers
a,
n (%)
968 (14.3) 1104 (15.1) 0.2071
b-blockers, n (%) 1605 (23.7) 1883 (25.7) 0.0066
Oral glucose lowering
drugs, n (%)
628 (9.3) 559 (7.6) 0.0005
Statins, n (%) 727 (10.7) 688 (9.4) 0.0084
Antithrombotics, n (%) 421 (6.2) 395 (5.4) 0.0386
Angiotensin receptor
blockers
b, n (%)
101 (1.5) 120 (1.6) 0.5301
Angiotensin converting
enzyme inhibitors
b, n (%)
1361 (20.1) 1459 (19.9) 0.7906
Numbers in brackets represent standard deviation, where no other
description is given.
aDihydropyridine substances.
bDiscontinued treatment before index prescription.
Time (months)
m
m
H
g
60
70
80
90
100
110
120
130
140
150
160
Diastolic
Mean arterial
Systolic
Candesartan
Losartan
No.*
Can.  5860  4011 3908 2558 1703 1228 837  481  224
%†  80.0  62.6 70.2 71.9 71.1 71.5 73.6 70.2 72.3
Los.  5370  3662 3740 2510 1663 1172 792  453  236
%†  79.3  61.7 70.8 73.9 72.4 71.5 67.1 71.6 72.2
0 6 12 18 24 30 36 42 48 54 60 66 72 78 84 90 96
Figure 2 Blood pressure during follow-up. *No, number of
patients with blood pressure readings; w, per cent blood pressure
readings among patients at risk; Los, losartan; Can, candesartan.
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Journal of Human HypertensionFigure 5 shows that the use of both losartan and
candesartan was according to prescribing recom-
mendations for hypertension. The losartan group
generally started with 50mg and up-titrated to fixed
combination 50/12.5mg. The candesartan group, on
the other side, mainly started with 4 and 8mg in
patients with higher blood pressure at baseline, þ1/
þ1mmHg. Within the first 6 months these patients
were up-titrated to 16 and 16/12.5mg. Within the
first 6 months losartan was up-titrated by 6.1% and
candesartan by 13.2%.
The frequency of fixed combination tablets
(ARBþhydrochlorothiazide) in the losartan group
rose from 24.7 to 60.5% (þ35.9%) compared with
an increase from 13.4 to 33.4% (þ20.0%) in the
candesartan group.
Table 2 Clinical outcomes obtained from primary care journals and Swedish national discharge and death registers
Losartan,
n (%) (n¼6771)
Candesartan,
n (%) (n¼7329)
Hazard ratio
(95% CI)
(unadjusted)
P value Hazard ratio
(95% CI)
(adjusted)
a
P value
Primary composite end point
b,c 676 (10.0) 575 (7.8) 0.79 (0.71–0.89) o0.0001 0.86 (0.77–0.96) 0.0062
Heart failure
c 164 (2.4) 101 (1.4) 0.58 (0.45–0.74) o0.0001 0.64 (0.50–0.82) 0.0004
Cardiac arrhythmias
c 210 (3.1) 163 (2.2) 0.73 (0.60–0.90) 0.0029 0.80 (0.65–0.98) 0.0330
Peripheral artery disease
c,d 68 (1.0) 40 (0.5) 0.61 (0.38–0.83) 0.0035 0.61 (0.41–0.91) 0.0140
Chronic ischemic heart disease 202 (3.0) 172 (2.3) 0.80 (0.66–0.99) 0.0350 0.86 (0.70–1.05) 0.1400
Myocardial infarction
c 138 (2.0) 123 (1.7) 0.85 (0.66–1.08) 0.1800 0.93 (0.73–1.19) 0.5600
Stroke
c,e 157 (2.3) 146 (2.0) 0.88 (0.70–1.10) 0.2600 0.95 (0.76–1.19) 0.6400
Hospitalization for unstable angina 26 (0.4) 21 (0.3) 0.77 (0.43–1.36) 0.3600 0.80 (0.45–1.42) 0.4500
Elective coronary revascularization 18 (0.3) 14 (0.2) 0.74 (0.37–1.48) 0.3900 0.78 (0.39–1.58) 0.4900
Cardiovascular mortality 75 (1.1) 66 (0.9) 0.83 (0.60–1.16) 0.2800 0.93 (0.66–1.29) 0.6500
Total mortality 155 (2.3) 156 (2.1) 0.96 (0.77–1.20) 0.7100 1.06 (0.85–1.32) 0.6200
New onset diabetes 318 (4.7) 309 (4.2) 0.92 (0.79–1.08) 0.3000 0.90 (0.77–1.05) 0.1900
aAdjusted for age, gender, diabetes, and index-year.
bPrimary composite end point consists of heart failure, cardiac arrhythmias, peripheral artery disease, chronic ischemic heart disease, myocardial
infarction, stroke, elective coronary revascularization, hospitalization for unstable angina, or cardiovascular mortality.
cIncludes fatal events.
dIncludes aortic aneurysms.
eIschemic, haemorrhagic stroke, and transient ischemic attacks.
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Figure 3 Kaplan–Meier curves of primary composite end point.
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Journal of Human HypertensionFigure 6 shows the use of other antihypertensive
medications (thiazides, calcium channel blockers, and
b-blockers) increased in both groups during follow-up.
The use of thiazides (both separate and in fixed
combination tablets) was more frequent in the losartan
group compared to the candesartan group. Slightly
more prescriptions of oral glucose lowering drugs at
baseline and during follow-up were observed in the
losartan group compared to the candesartan group.
Sensitivity analyses
When additionally adjusting for lipid lowering
drugs, thiazides, b-blockers, and antithrombotics
the risk of CVD in the candesartan group remained
significantly lower (HR 0.84, 95% CI 0.75–0.94,
P¼0.0030). When adding systolic blood pressure to
the adjustments (age, gender, diabetes, index year,
lipid lowering drugs, thiazides, b-blockers, and
antithrombotics), the number of patients available
for a survival analysis was reduced by 20%
(n¼11230) because of absent blood pressure values.
However, despite this loss of patients in the survival
model, the risk remained similar (HR 0.87, 95% CI
0.77–0.98, P¼0.0250) compared with the primary
survival model.
To further evaluate potential effects of differences
at baseline, patients without a history of diabetes or
treated with any glucose lowering drug (n¼11 596)
were analysed separately. When adjusting for age,
gender, and index year, the risk of CVD remained
similar (HR 0.86, 95% CI 0.76–0.98, P¼0.0210) in
patients without diabetes.
Discussion
In this study, 14100 patients in a primary preven-
tion setting were treated with either losartan
(n¼6771) or candesartan (n¼7329). They fulfilled
the inclusion criteria of being hypertensive and
without previously known CVD. Patients were
followed for a median of 2 years with a total of
36339 patient years, using the combination of
patient journal data in 72 primary care centres and
the mandatory Swedish national hospital discharge
and cause of death registers. There was a substantial
blood pressure reduction after treatment with both
drugs, with no difference in blood pressure between
the two treatment groups during the follow-up
period. Our results showed that candesartan was
more effective than losartan in reducing the risk of
primary composite end point, HR 0.86 (95% CI
0.77–96, P¼0.0062).
We used a method that uses the strengths of
electronic patient registers, which cover large
patient groups, making them increasingly accessible
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Figure 4 Kaplan–Meier curves for separate end points. Los, losartan; Can, candesartan.
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this method provides large number of patients in
short time and at a rather low cost, some limitations
are inevitable.
One of the limitations with this method is the
absence of recorded baseline data in the electronic
patient primary care journal. Blood pressure record-
ings were only registered in 80% of all the patients
at baseline, leaving 20% unaccounted for, which
was similar in both groups. The candesartan group
had a slightly higher baseline blood pressure
compared to the losartan group. When adjusting
for blood pressure we lost 20% of the patient
material in the survival model, but the results
remained similar. This type of large register study
will always be associated with incomplete data.
However, the large number of patients may com-
pensate for this weakness.
When including patients over a longer time span,
the possibility of variations in the patient handling
may be a confounder. For example, an important
potential confounding factor could have been varia-
tion in hypertensive treatment, favouring inclusion
either in the losartan or candesartan group. The
annual frequency of inclusion to the losartan or
candesartan group from 1999 to 2007 was, however,
similar. This suggests that there was a similar
assessment of hypertensive patients with no differ-
ences between groups regarding the time point of
inclusion.
Some confounders are difficult to measure and
therefore not usable in a survival model. These
confounders may have changed the baseline risk
among the patients (that are the recording of
diagnoses, new indications, reimbursement, guide-
lines, marketing, and shift in the ICD system or
continuous updating of the software for electronic
patient journal systems). Adjusting for all these
potential confounders is difficult and we, therefore,
made adjustments for the year of index prescription
to minimize the possible effects of temporal changes
with regard to the above parameters.
Registry data are to a certain degree associated
with absent laboratory data (blood samples and
blood pressure measurements) at specific time
intervals. However, in our study the frequency of
laboratory data did not differ markedly between the
two groups, suggesting similar need of medical
attention at baseline.
We have adjusted for differences in observed CVD
risk between the two groups at inclusion. However,
differences in undetected risk at inclusion may also
be of concern. When excluding patients because of
earlier CVD, more patients (9.9%) were excluded
from the losartan group. Consequently, the risk of
undetected CVD may have been higher in this group,
requiring a reliable method of finding CVD before
inclusion. To exclude patients with earlier CVD,
patient journals in primary care were searched for
CVD diagnoses on average 5.8 years before inclusion
and drugs associated with CVD before inclusion.
Patients were also scanned for hospitalizations
caused by CVD in the Swedish Hospital Discharge
Register, which has had mandatory registration
since 1984.
16 The combination of these two search
techniques should therefore have lowered the risk of
skewed CVD prevalence at baseline as all patients
with documented CVD in the primary care journals,
hospital records, or indicated by drug prescriptions
were excluded. Thus, we feel that we have reason-
able well excluded the risk of confounding by
indication. The increased prescriptions of antith-
rombotics and statins at baseline in the losartan
group could have also signalled a systematic failure
in CVD detection before inclusion. However, having
more diabetic patients in the losartan group may
have translated into more prescriptions of drugs
used in the primary prevention of CVD. Further-
more, the HR for CVD was unchanged compared to
the primary survival model when additionally
adjustments were made for baseline differences in
lipid lowering drugs, thiazides, b-blockers, and
antithrombotics.
The study had a follow-up time of median 2.0
years, and 47% of the patients were followed for
2 years. Compared to the LIFE study (93% over
2 years), this follow-up intensity may seem low and
stresses the need of large patient groups when
performing a register study with this method.
4 The
explanation for this drop in patient numbers in our
study could partly be due to the lack of adherence to
the primary treatment of hypertension (approxi-
mately 30%), which was also described in other real
life studies.
23 Randomized controlled trials have
also had a similar follow-up time as those in our
study. In the JUPITER trial the median follow-up
time was 1.9 years and only 43% of the patients
were followed for 2 years.
25
Our main finding was a risk reduction in CVD
mainly determined by heart failure, cardiac ar-
rhythmias, and peripheral artery disease. The risk
of heart failure was reduced by 36% in the
candesartan group. Heart failure may be a result of
left ventricular hypertrophy and/or myocardial
infarction, and is therefore responsive to the
myocardial remodelling properties of a drug. Both
losartan and candesartan have beneficial remodel-
ling effects on hypertrophic myocardium.
4,26 The
risk of cardiac arrhythmias in the candesartan group
was 20% lower and may be explained by the lower
incidence of heart failure. Alternatively, the lower
incidence of atrial fibrillation may explain the
lower risk of heart failure.
27 We believe that the
lower risk of new heart failure and cardiac arrhyth-
mias in the candesartan group may be due to a
more potent inhibition of AT1 receptors as this
occurred at the same level of blood pressure control
and in patient groups with similar baseline char-
acteristics.
10
Furthermore, candesartan has reported positive
effects on risk markers such as high oxidative stress
and increased coagulability compared to losartan,
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cations.
28 Interestingly, the risk of peripheral artery
disease was lower (39%) in the candesartan group
compared to the losartan group. A possibility is that
the peripheral circulation may be reduced in
patients with heart failure leading to earlier is-
chemic symptoms in the lower limbs.
There was no difference between the two
treatment groups in blood pressure throughout
the study, with an average blood pressure of
approximately 145/85mmHg in both groups.
The blood pressures in this study are office
readings and a potential difference in 24h blood
pressure has not been investigated and can there-
fore not be excluded. Slightly elevated baseline
blood pressure in the candesartan group suggests
that this group may have had a higher baseline
CVD risk. However, after adjustment for baseline
systolic blood pressure, only small effects in the
survival analyses were seen. The similar blood
pressure in both groups after inclusion may
explain why we did not observe any differences
in the risk of stroke. The LIFE study, which
compared losartan and atenolol, did show a blood
pressure independent reduction in stroke risk in
favour of losartan, but atenolol may be an inferior
drug for stroke prevention.
4,29 Our results suggest
that candesartan and losartan have similar effects
on stroke prevention.
Up-titration of the ARB dose from the index
prescription was somewhat higher in the candesar-
tan group compared to the losartan group, which
may be seen in light of the different start dosage
alternatives and the next dose step. The losartan
group was generally started with ARB only and up-
titrated by adding thiazides, without changing the
ARB dose. The candesartan group, on the other side,
was mainly started with lower ARB dosages in
patients with significantly higher blood pressure at
baseline. Within the first 6 months those patients
were up-titrated by both increasing ARB dosage and
adding thiazides. The initial ARB dosage was
therefore relatively lower during the first 6 months
in the candesartan group compared with the
losartan group. The ARB use was therefore consid-
ered reasonably comparable in the two groups after
up-titration.
In this study, the initial and continued use of
thiazides was more frequent in the losartan group
compared to the candesartan group. The increased
use of thiazides in the losartan group support
reports of an improved blood pressure lowering
effect with candesartan compared with losartan
when given as monotherapy.
10,30,31 Recently, the
LIFE study group reported that concomitant thia-
zide therapy was associated with reduced cardio-
vascular morbidity and mortality, independent of
blood pressure and electrocardiographic evidence
of left ventricular hypertrophy.
32 Consequently, the
use of more concomitant thiazide treatment in
patients treated with losartan should therefore
have potentially reduced CVD risk in this group.
Other concomitant antihypertensive treatments
(calcium channel blocker and b-blocker) did not
differ during the observation period. We have
therefore no reason to believe that the use of
additional antihypertensive drugs could have
influenced our results.
Conclusion
We believe that our study method provides a new
tool that can be used to study existing treatments,
providing rapid results at a low cost. However, it
requires the wide use of similar electronic patient
journal systems in primary care and a long tradition
with nationwide hospitalization and cause of death
registers. Sweden offers this combination and pro-
vides the opportunity to study differences between
treatments, not feasible to assess in randomized
clinical trials.
The results of this study suggest that there is a
blood pressure independent risk reduction in CVD
with candesartan compared to losartan in the
primary treatment of hypertension. This suggests
that pharmacological differences within the ARB
class may translate into important clinical effects.
Furthermore, the study of a real life situation may
provide an additional method that can be used to
assess existing and future treatments.
What is known about the topic
K Angiotensin receptor blockers have different
pharmacological properties. Losartan and candesartan have
significant differences regarding receptor binding when
compared.
10–12
K Differences in blood pressure reduction have been reported
between ARBs.
28,29 However, no study has been performed to
assess possible differences in risk of cardiovascular disease
within this class of drugs.
K The use of electronic patient journals increases continuou-
sly with time, both in primary-, and hospital care. Those
large databases are accessible and are increasingly used for
epidemiological studies, also in other countries.
20–22
What this study adds
K The choice between two different ARBs (losartan and
candesartan) did not seem to affect the blood pressure levels
during treatment in a real life clinical setting. However,
increased use of thiazides in the losartan group was observed
to achieve equal blood pressure reduction.
K When comparing the hypertensive primary treatment with
two of the most used ARBs, losartan vs candesartan,
differences in the risk of cardiovascular disease was
observed. The candesartan group had lower risk of
cardiovascular disease compared with the losartan group.
K In countries with nationwide use of electronic patient
journals, it is possible to combine separate patient databases
from primary-, hospital care, and cause of death register.
Assessment of established treatment in a real life primary
care setting is possible to be performed rapid and rather
inexpensive, using hard disease events as end points.
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